Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study)

• Príomhchruthaitheoirí: Andrea Chiricozzi (Údar), Matteo Megna (Údar), Alessandro Giunta (Údar), Carlo Giovanni Carrera (Údar), Paolo Dapavo (Údar), Anna Balato (Údar), Piergiorgio Malagoli (Údar), Stella Mazzoccoli (Údar), Aurora Parodi (Údar), Silvia Sabatino (Údar), Carlotta Buzzoni (Údar), Chu-Han Huang (Údar), Alessandra Narcisi (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Purpose Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A approved for the treatment of moderate-to-severe plaque psoriasis. The objective of this study was to describe the real-world long-term effectiveness of ixekizumab in patients with plaque psoriasi...